Intralipid® may represent a new hope for patients with reproductive failures and simultaneously an over-immune endometrial activation

Double blind placebo versus Intralipid® studies should be conducted. Intralipid® may be an option to explore in RIF patients who exhibit an over-immune activation of uNK cells.